DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Zalcberg JR, Verveij J, Casali PG. et al.
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
Eur J Cancer 2005; 41: 1751-1757
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.